Novartis, Ophthotech Sign Deal for Fovista – Analyst Blog – NASDAQ

Novartis, Ophthotech Sign Deal for Fovista – Analyst Blog
NASDAQ
We note that Novartis’ Lucentis is approved for four ocular indications in over 100 countries – wet age-related macular degeneration (wet AMD), visual impairment due to diabetic macular edema (DME), visual impairment due to macular edema secondary to …

…read more

Source: Wet Macular Degeneration News From Google News

Leave a Comment